Abstract

Background: Pancreatic ductal adenocarcinoma remains a highly aggressive cancer with limited treatment options and poor prognosis. Pembrolizumab has shown potential in patients with micro satellite instability-high tumors. We report a rare case of complete remission of metastatic pancreatic cancer.
Methods: A 58-year-old male with MSI-H advanced PDAC, who progressed during adjuvant and metastatic first-line treatment, was treated with pembrolizumab showed significant clinical improvement.
Results: Pembrolizumab led to complete response. At the time of the report, the patient had durable response of 13 months.
Conclusions: This case demonstrates the promising role of pembrolizumab in MSI-H advanced pancreatic cancer.

DOI: 10.7754/Clin.Lab.2025.250144